RxDoctor Payments Data

Alexandra Miller, PA

Physician Assistant · Terre Haute, INNPI 1760043566

Payments from drug & device makers

$2,706in general payments, 2019–2025

Across 62 payments — averaging $43.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$610
  • Johnson & Johnson$572
  • Boehringer Ingelheim$448
  • Novo Nordisk$234
  • Edwards Lifesciences$225
  • Novartis$211
  • plus $406 from 8 others

What the payments were for

  • Food & beverage$2,68699%
  • Education$201%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,706 in reported general payments places this provider in the 85th percentile of 1,955 physician assistant providers in Indiana.

See all physician assistant providers in Indiana

Medicare billing

Part B allowed, 2024
$66,805
Medicare patients
514
Services billed
991

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin207$199,903
XareltoRivaroxaban87$106,452
EliquisApixaban76$78,357
EntrestoSacubitril/Valsartan49$48,493
OzempicSemaglutide30$29,007
Repatha SureclickEvolocumab23$21,957
FarxigaDapagliflozin Propanediol14$18,034
Metoprolol Succinate321$3,428
Atorvastatin Calcium348$2,463
Ranolazine ErRanolazine35$2,058
Amlodipine Besylate217$1,396
ClopidogrelClopidogrel Bisulfate135$1,212
Carvedilol162$1,170
Rosuvastatin Calcium99$1,135
Isosorbide Mononitrate ErIsosorbide Mononitrate130$940

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$448$199,903207 claims
Johnson & JohnsonXarelto$572$106,45287 claims
NovartisEntresto$211$48,49349 claims
Novo NordiskOzempic$234$29,00730 claims
AstraZenecaFarxiga$25$18,03414 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,955 physician assistant providers in Indiana.

Other physician assistant in Terre Haute

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →